TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TCRX 10.04.2024
About Gravity Analytica
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39thAnnual Meeting being held November 6 – 10 in Houston, TX and virtually.
Poster Presentation Details:
Title:Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid TumorsAuthors:Rutuja Kulkarni, Akshat Sharma, Vivin Karthik, Kenneth L Jahan, Rakshi Bala, Nicolas Gaspar, Amanda Kordosky, Daniel C Pollacksmith, Alok Das Mahopatra, Maytal Bowman, Drashti Shah, Victor Ospina, Sanket Revadkar, Skyler Martinez, Ryan E Kritzer, Jayanth Jawahar, Hana Husic, Shoshana Bloom, Emily Miga, Rachel Lent, Chandan K Pavuluri, Carolyn Hardy, Abigail Dooley, Alex Cristofaro, Zhonghua Zhu, Livio Dukaj, Antoine Boudot, Kimberly M Cirelli, Mollie M Jurewicz, Cagan GurerAbstract Number:375Session Date/Time:Friday, November 8; 9:00 a.m. - 7:00 p.m. Central TimeLocation:Exhibit Halls AB – George R. Brown Convention Center
Title:Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA HeterogeneityAuthors:Maytal Bowman, Amanda Kordosky, Daniel Pollacksmith, Alok Das Mohapatra, Debanjan Goswamy, Victor Ospina, Sanket Revadkar, Shubhangi Kamalia, Skyler Martinez, Gaenna Rogers, Teagan Parsons, Dalena Nguyen, Jenny Tadros, Ira Jain, Alexander Cristofaro, Jenna LaBelle, Ribhu Nayar, Nancy Nabilsi, Antoine BoudotAbstract Number:359Session Date/Time:Friday, November 8; 9:00 a.m. - 7:00 p.m. Central TimeLocation:Exhibit Halls AB – George R. Brown Convention Center
Title:Development of a Target Agnostic Platform to Assess the Reactivity of T Cell Receptor (TCR)-Engineered T Cell (TCR-T) Therapies to Primary Human TissuesAuthors:Sveta Padmanabhan, Shubhangi Kamalia, Drashti Shah, Shazad A Khokhar, Sadie Lee, Daniel C Pollacksmith, Kimberly M Cirelli, Vivin Karthik, Jenny Tadros, Teagan Parsons, Nancy Nabilsi, Andrew Ferretti, Dalena M.V. Nguyen, Livio Dukaj, Ryan E Kritzer, Emily Miga, Alexander Cristofaro, Chandan K Pavuluri, Elisaveta Todorova, Tyler M Sinacola, Savannah G Szemethy, Kyra N Sur, Vandana Keskar, Carolyn Hardy, Hsin-Ho Huang, Zhonghua Zhu, Cagan Gurer, Antoine J Boudot, Sonal Jangalwe, Ribhu Nayar and Gavin MacBeathAbstract Number:384Session Date/Time:Saturday, November 9; 9:00 a.m. - 8:30 p.m. Central TimeLocation:Exhibit Halls AB – George R. Brown Convention CenterA copy of the presentation materials will be added to the “Publications” section of the Company’s website attscan.comonce presentations have concluded.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATMPhase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.
Contacts
Heather SavelleTScan Therapeutics, Inc.VP, Investor Relations857-399-9840hsavelle@tscan.com
Maghan MeyersArgot Partners212-600-1902TScan@argotpartners.com
